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Abstract
Background: The Metabolic syndrome (MS) consists of central obesity, glucose intolerance, hyperinsulinemia, low
high density lipoproteins, high triglycerides and hypertension. Different studies have observed that MS causes
microvascular complications in patients with type 2 diabetes. The aim of the study was to find out the prevalence
of MS in the Indian population with type 2 diabetes mellitus in relation to gender, duration of diabetes, and to
evaluate the influence of MS and its individual components on microvascular complications such as diabetic
retinopathy, diabetic nephropathy and diabetic neuropathy.
Methods: A population-based cross sectional survey was conducted with 1414 patients having type 2 diabetes
mellitus. The International Diabetes Federation (IDF) criteria were used to identify the metabolic syndrome. Diabetic
retinopathy was graded using the stereoscopic digital fundus photography. Neuropathy was assessed by
measuring the vibration perception threshold through a sensitometer. Nephropathy was diagnosed by the
presence of microalbuminuria in the first morning urine sample.
Results: The age and gender adjusted prevalence of MS, using the IDF criteria, in the South Indian population was
73.3%. The prevalence was higher in women (83.3%), compared to men (65.3%). In subjects with diabetes mellitus,
without and with MS, the prevalence of retinopathy was 21.3% and 16.9% (p = 0.057); prevalence of nephropathy
was 20.5% and 18.0% (p = 0.296), and prevalence of neuropathy was17.2% and 19.4% (p = 0.353) respectively.
Overall and in women, the clustering of MS components led to an increase in the prevalence of diabetic
nephropathy. The prevalence of retinopathy and neuropathy in MS subjects, who had diabetes for < 10 years, was
more in both men and women; it was more in women but not in men when the duration of diabetes varied from
11-20 years.
Conclusions: The association of MS with microangiopathies decreased with an increase in the duration of
diabetes. MS behaved differently in men and women. It may need to be managed differently in the two groups.
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The Metabolic Syndrome (MS) is a constellation of central
obesity, glucose intolerance, hyperinsulinemia, low high
density lipoproteins (HDL), high triglycerides and hyper-
tension [1]. It is associated with a high risk of coronary
heart disease (CHD) and premature mortality [2]. Besides
resulting in macrovascular complications, there is growing
evidence that MS, like diabetes mellitus, causes microvas-
cular complications in patients with type 2 diabetes melli-
tus [3-5]. Nearly 70-80% of the population with diabetes
mellitus is diagnosed with MS [6-8].
The correlation between MS and macro- and microvas-
cular complications, in patients with diabetes mellitus, has
been shown previously in American and European sub-
jects [9-11]. The data in the Asian population is scanty
and controversial. In Japan, the Funagata Study observed
that MS, using the definition of the International Diabetes
Federation (IDF), was associated with microvascular
changes in the retina [12]. However, Terauchi et al [13]
found that neither the presence of MS (as defined by the
IDF guideline) nor an increased waist circumference
increased the risk of micro- or macrovascular complica-
tions in Japanese patients with type 2 diabetes mellitus.
The Asian population is somewhat different from the
Caucasian population. The incidence of CHD and the
absolute risk of death from CHD, at the same level of
blood pressure, is lower in Asians, more so in popula-
tions with diabetes [14,15]. The prevalence of obesity
and its impact on cardiovascular disease is also different
in Asians, compared to Caucasians [16].
The present population-based study aims to find out
the prevalence of MS in the Indian population with type
2 diabetes mellitus in relation to gender, duration of dia-
betes, and to evaluate the influence of MS and its indivi-
dual components on microvascular complications such
as diabetic retinopathy (DR), diabetic nephropathy and
diabetic neuropathy.
Methods
The sample population was recruited from the SN-
DREAMS 1 study which was a population-based cross-
sectional study. The methodology has been described
elsewhere [17]. The study population was selected by
multistage systematic random sampling. The sampling
was done in two stages: selection of divisions using
computer generated random numbers, and selection of
study subjects randomly from each selected division. A
target sample size was calculated based on the following
assumptions: the prevalence of diabetic retinopathy was
assumed to be 1.3%, with a relative precision of 25%, a
drop out rate of 20% and a design effect of 2. The sam-
pling was stratified based on the socio-economic criteria.
Ten divisions were selected and 600 individuals were
enumerated from each division to meet the target. Thus,
5830 subjects from the general population aged ≥ 40
years were enumerated.
Of the 5830 subjects enumerated, 1414 subjects with
diabetes (both known and newly diagnosed) were ana-
lyzed for the study (the response rate for the first fasting
blood sugar estimation was 96.20%; the response rate for
the base hospital examination was 85.60%; 8.7% were
non-diabetic, after the second blood sugar estimation,
and 0.78% retinal images were un-gradable). Subjects
with diabetes were identified based on the American
Diabetes Association criteria and they underwent a
detailed examination at the base hospital [18].
After eight hours of overnight fasting, the fasting
blood sample was taken to estimate the plasma glucose
and serum lipids. For those with provisional diabetes,
confirmation of diabetes wasd o n eb yr e - e s t i m a t i o no f
fasting blood glucose by enzymatic assay; glucose was
oxidized by glucose oxidase to produce gluconate and
hydrogen peroxide, which was then detected photome-
trically. A biochemical analysis was done on Merck
Micro Lab 120, semi automated analyzer. The total
serum cholesterol (CHOD-POD method), HDL (after
protein precipitation CHOD-POD method) and serum
triglycerides (CHOD-POD) were estimated.
Anthropometric measurements including weight,
height, waist and hip measurements were obtained using
standardized techniques. The blood pressure was
recorded, in the sitting position, in the right arm to the
nearest 2 mm Hg using the mercury sphygmoman-
ometer (Diamond Deluxe BP apparatus, Pune, India).
Two readings were taken, five minutes apart, and their
mean was taken as the blood pressure.
The study was approved by the Institutional Review
Board, and a written informed consent was obtained
from the subjects as per the Helsinki declaration [19].
Definitions
Metabolic syndrome
MS was defined using the International Diabetes Federa-
tion (IDF) consensus group guidelines as abdominal
obesity (waist circumference ≥ 90 cm for men and ≥ 80
cm for women) plus two or more of the following risk
factors: blood pressure ≥ 130/85 mm Hg, fasting plasma
glucose ≥ 5.6 mmol/l (100 mg/dl) or pre-existing dia-
betes, serum triglycerides ≥ 1.7 mmol/l (≥ 150 mg/l)
and HDL levels < 1.03 mmol/l (< 40 mg/dl) for men
and < 1.29 mmol/l (< 50 mg/dl) for women [20].
Diabetic Retinopathy
All patients had their fundi photographed using the 45°
four-field stereoscopic digital photography. The diagno-
sis of DR was based on the modified Klein classification
(Modified Early Treatment Diabetic Retinopathy Study
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Page 2 of 9scales) [21]. DR was divided into mild, moderate and
severe non-proliferative diabetic retinopathy (NPDR)
and proliferative diabetic retinopathy (PDR); clinically
significant macular edema (CSME) was graded as absent
or present [22]. This grading was done by two indepen-
dent observers in a masked fashion; the grading agree-
ment was high (k = 0.83) [17].
Diabetic Nephropathy
The microalbuminuria was estimated, using the first
morning urine sample, by a semi-quantitative procedure
(Clintek 50 Bayer Urine Analyzer). Subjects were con-
sidered to have microalbuminuria, if the Albumin Crea-
tinine Ratio (ACR) was between 30 and 299 mg/g [23].
Diabetic Neuropathy
Diabetic neuropathy assessment was done by measuring
the Vibration Perception Threshold (VPT) using a sen-
sitometer. The VPT was measured, by a single observer,
by placing a biothesiometer probe perpendicular to the
distal plantar surface of the great toe of both the legs.
The VPT was measured at a voltage level when the
patient felt the first vibration sensation. The mean VPT
measure of the three readings, of both the legs, was con-
sidered for the analysis. The presence of diabetic neuro-
pathy was considered if the VPT value was > 20 V [24].
Statistical analysis
A computerized database was created for all the records.
A statistical package for the Social Sciences-SPSS (ver-
sion 9.0) was used for statistical analysis. All the data
were expressed as mean ± S.D or as percentage. The
statistical significance was assumed at p value ≤ 0.05.
Univariate and multivariate logistic regression analyses
were performed to elucidate the risk factors for micro-
angiopathies. The Odds Ratio (OR), with 95% confi-
dence intervals, was calculated for the studied variables.
Results
The prevalence of MS in our subjects, with type 2 dia-
betes mellitus, was 73.8% (95% CI 71.5-76.0); the age
and gender adjusted prevalence being 73.3% (95% CI
73.2-73.3). The prevalence was higher in women 83.3%
(95% CI 80.4-86.1) compared to men 65.3% (95% CI
61.9-68.7). Table 1 shows the prevalence of MS in rela-
tion to gender and the duration of diabetes in subjects
with type 2 diabetes mellitus. The prevalence of MS in
men decreased with an increase in the duration of dia-
betes (67.4%, 59.7% and 39.1% in duration < 10 years,
10-20 years and > 20 years respectively, trend p = 0.002)
whereas it remained almost similar in women (83.8%,
79.1% and 81.8%, trend p = 0.401).
Table 2 shows the age and gender adjusted prevalence
of individual components of MS in subjects with type 2
diabetes mellitus. The prevalence of increased waist
circumference was 75.5% (95% CI 75.4-75.6); of
hypertension, 75.3%, (95% CI 75.2-75.3%); of elevated
serum triglycerides, 37.5% (95% CI 37.5-37.6); and of
reduced serum HDL, 71.3% (95% CI 71.2-71.3%).
Table 3 shows the baseline demographic and labora-
tory characteristics of the study population. Overall,
subjects with MS had a higher serum non HDL choles-
terol (p = 0.029). However, they had lesser duration of
diabetes than those without MS (p < 0.0001). On evalu-
ating men and women separately, men with MS showed
similar findings except for a raised level of hemoglobin
in subjects with MS (p = 0.013). But in women with
MS, the duration of diabetes and serum non HDL cho-
lesterol were not significantly different (p = 0.084 and
0.488 respectively), and the levels of total serum
Table 1 Prevalence of Metabolic Syndrome in relation to
gender and duration of Diabetes in the study population
Duration of Diabetes Prevalence of Metabolic Syndrome
(Years) n % (95% CI) Trend p
Overall
0-10
(N = 1194)
901 75.5 [73.0-77.9]
11-20
(N = 186)
124 66.7 [59.9-73.4]
>2 0
(N = 34)
18 52.9 [36.2-69.7] 0.0002
Total (N = 1414) 1043 73.8 [71.5-76.0]
Men
0-10 (N = 608) 410 67.4 [63.7-71.2]
11-20
(N = 119)
71 59.7 [50.8-68.5]
>2 0
(N = 23)
9 39.1 [19.2-59.1] 0.002
Total
(N = 750)
490 65.3 [61.9-68.7]
Women
0-10 (N = 586) 491 83.8 [80.8-86.8]
11-20
(N = 67)
53 79.1 [69.4-88.8]
>2 0
(N = 11)
9 81.8 [59.0-104.6] 0.401
Total
(N = 664)
553 83.3 [80.4-86.1]
N, Total population; n, Population with metabolic syndrome.
Table 2 Prevalence of individual components of
Metabolic Syndrome
Prevalence of Metabolic Syndrome
Components N n % * [95% of CI]*
Increased Waist circumference 1414 1077 75.5 [75.4-75.6]
Hypertension 1414 1026 75.3 [75.2-75.3]
Elevated serum triglyceride 1414 547 37.5 [37.5-37.6]
Reduced serum HDL-Cholesterol 1414 1026 71.3 [71.2-71.3]
>N, Total population; n, Population with metabolic syndrome;
Age and gender adjusted.
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pared to subjects without MS (p = 0.048 and 0.002
respectively). As observed in men, the hemoglobin level
was significantly higher in women with MS (p = 0.003).
Table 4 evaluates the effect of MS on the prevalence
of microvascular complications of diabetes. In subjects
with diabetes mellitus, without and with MS, the preva-
lence of retinopathy was 21.3% and 16.9% (p = 0.057);
prevalence of nephropathy was 20.5% and 18.0% (p =
0.296) and prevalence of neuropathy was17.2% and
19.4% (p = 0.353) respectively. When evaluated sepa-
rately, in men and women, the diagnosis of MS was not
significantly associated with the presence of microvascu-
lar complications in our study population except for a
lower prevalence of nephropathy in men with MS
(p = 0.029).
Table 5 shows the effect of aggregation of more num-
ber of components of MS on the prevalence of microan-
giopathies. The IDF definition of MS requires central
obesity to be the essential criterion. Since our whole
study population was diabetic, the presence of diabetes
or raised plasma glucose also became an unchangeable
criterion in our study cohort. To study the desired out-
come, we grouped the patients into three sets, in
increasing order of presence of three, four or five
criteria of MS. When patients were grouped in such a
w a y ,t h ep r e v a l e n c eo fd i a b e t i c retinopathy, overall and
in men, was not different. In women, however, the pre-
valence of retinopathy increased with a rise in the num-
ber of MS components (12.6%, 20.1% and 16.4%, trend
p = 0.193 overall; 17.5%, 22.8% and 21.6%, trend p =
0.779 in men; 6.5%, 18.0% and 15.0%, trend p = 0.049 in
w o m e n ) .O v e r a l la n di nw o m e n ,t h ec l u s t e r i n go fM S
components led to an increase in the prevalence of dia-
betic nephropathy. However, there was no such trend in
men (13.9%, 18.5% and 21.7%, trend p = 0.013 overall;
11.6%, 19.2% and 26.3%, trend p = 0.001 for women;
15.8%, 17.6% and 15.9%, trend p = 0.945 in men). For
diabetic neuropathy, the prevalence was not different
overall and in men, but it increased with grouping of
MS components in women (21.2%, 16.8% and 21.6%,
trend p = 0.929 overall; 26.9%, 17.1% and 19.2%, trend
p = 0.077 in men and 14.0%, 16.6% and 23.6%, trend
p = 0.003 in women).
Table 6 shows the influence the duration of diabetes
has on the prevalence of microangiopathies in patients
with and without MS. The prevalence of retinopathy
and neuropathy in MS subjects, who had diabetes for
< 10 years, was more in both men and women; it was
more in women but not in men when the duration of
Table 3 Baseline characteristics of the study population
Metabolic Syndrome
Variables Overall Men Women
Absent Present p Absent Present p Absent Present p
n = 371 n = 1043 n = 260 n = 490 n = 111 n = 553
Age (years) 57.0 ± 10.3 56.1 ± 9.9 0.119 57.1 ± 10.5 56.8 ± 10.5 0.664 56.8 ± 9.8 55.4 ± 9.4 0.181
HbA1C (%) 8.3 ± 2.4 8.2 ± 2.1 0.366 8.3 ± 2.4 8.2 ± 2.1 0.475 8.2 ± 2.6 8.1 ± 2.1 0.687
Duration of diabetes (years) 6.6 ± 7.5 5.1 ± 5.7 < 0.0001 7.1 ± 8.0 5.7 ± 6.0 0.008 5.5 ± 5.6 4.6 ± 5.3 0.084
Total serum cholesterol (mg/dl) 184.5 ± 40.9 187.2 ± 40.7 0.266 178.1 ± 38.4 183.2 ± 38.4 0.081 199.5 ± 42.8 190.8 ± 42.3 0.048
Serum LDL cholesterol (mg/dl) 113.2 ± 35.9 111.8 ± 35.2 0.506 106.8 ± 33.6 106.3 ± 33.8 0.845 128.2 ± 37.2 116.7 ± 35.8 0.002
Serum Non HDL cholesterol (mg/dl) 3.7 ± 1.0 3.8 ± 1.0 0.029 3.6 ± 0.9 3.8 ± 0.9 0.009 3.9 ± 1.0 3.9 ± 1.1 0.488
Hemoglobin (gm/dl) 13.8 ± 1.8 13.8 ± 1.4 0.884 14.2 ± 1.9 14.5 ± 1.4 0.013 12.7 ± 1.3 13.1 ± 1.1 0.003
HbA1C (%), Glycosylated hemoglobin; LDL, Low density lipoprotein; HDL, High-density lipoprotein.
Table 4 Comparison of prevalence of microangiopathies in the study population with and without Metabolic
Syndrome
Metabolic Syndrome Diabetic Retinopathy, n = 255 p Diabetic Nephropathy, n = 264 p Diabetic Neuropathy, n = 264 p
Overall
Absent (n = 371) 79 (21.3) 0.057 76 (20.5) 0.296 63 (17.2) 0.353
Present (n = 1043) 176 (16.9) 188 (18.0) 201 (19.4)
Men
Absent (n = 260) 61 (23.5) 0.241 60 (23.1) 0.029 46 (17.9) 0.304
Present (n = 490) 97 (19.8) 81 (16.5) 103 (21.1)
Women
Absent (n = 111) 18 (16.2) 0.599 16 (14.4) 0.222 17 (15.6) 0.556
Present (n = 553) 79 (14.3) 107 (19.3) 98 (17.9)
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Page 4 of 9Table 5 Effect of clustering of components of Metabolic Syndrome on microangiopathies
Prevalence of Microangiopathies
Components of MS Diabetic Retinopathy Diabetic Nephropathy Diabetic Neuropathy
N n % Trend p n % Trend p n % Trend p
Overall (n = 1043)
+ Any one 309 39 12.6 43 13.9 65 21.2
+Any two 448 90 20.1 0.193 83 18.5 0.013 75 16.8 0.929
+ Any three 286 47 16.4 62 21.7 61 21.6
Men (n = 490)
+ Any one 171 30 17.5 27 15.8 46 26.9
+Any two 193 44 22.8 0.779 34 17.6 0.945 33 17.1 0.077
+ Any three 126 23 18.3 20 15.9 24 19.2
Women (n = 553)
+ Any one 138 9 6.5 16 11.6 19 14.0
+Any two 255 46 18.0 0.049 49 19.2 0.001 42 16.6 0.030
+ Any three 160 24 15.0 42 26.3 37 23.6
MS, Metabolic Syndrome; MS absent, Diabetes only or Diabetes + Obesity; + Any one, Diabetes + Obesity + Any of hypertension, reduced HDL or elevated
triglyceride; + Any two, Diabetes + Obesity + Any two of hypertension, reduced HDL or elevated triglyceride; + Any three, Diabetes + Obesity + All three of
hypertension, reduced HDL or elevated triglyceride; N, Total population with metabolic syndrome; n, Population with metabolic syndrome having
microangiopathies.
Table 6 Effect of duration of Diabetes on the prevalence of microangiopathies in study population with or without
Metabolic Syndrome
Prevalence of Microangiopathy
Variables Groups Duration (0-10 years) p Duration (11-20 years) p Duration (> 20 years) p
Overall
Retinopathy MS Absent 48 (28.2) < 0.0001 25 (34.7) 0.013 6 (46.2) 1.000
MS Present 122 (71.8) 47 (65.3) 7 (53.8)
Nephropathy MS Absent 61 (29.6) < 0.0001 12 (22.6) < 0.0001 3 (60.0) 1.000
MS Present 145 (70.4) 41 (77.4) 2 (40.0)
Neuropathy MS Absent 38 (19.9) < 0.0001 18 (31.0) 0.005 7 (46.7) 1.000
MS Present 153 (80.1) 40 (69.0) 8 (53.3)
Men
Retinopathy MS Absent 36 (34.3) 0.002 19 (43.2) 0.451 6 (66.7) 0.508
MS Present 69 (65.7) 25 (56.8) 3 (33.3)
Nephropathy MS Absent 46 (43.4) 0.206 11 (36.7) 0.200 3 (60.0) 1.000
MS Present 60 (56.6) 19 (63.3) 2 (40.0)
Neuropathy MS Absent 24 (24.2) < 0.0001 16 (40.0) 0.268 6 (60.0) 0.754
MS Present 75 (75.8) 24 (60.0) 4 (40.0)
Women
Retinopathy MS Absent 12 (18.5) < 0.0001 6 (21.4) 0.004 0 (0.0) 0.125
MS Present 53 (81.5) 22 (78.6) 4 (100.0)
Nephropathy MS Absent 15 (15.0) < 0.0001 1 (4.3) < 0.0001 0 (0.0) NA
MS Present 85 (85.0) 22 (95.7) 0 (0.0)
Neuropathy MS Absent 14 (15.2) < 0.0001 2 (11.1) 0.001 1 (20.0) 0.375
MS Present 78 (84.8) 16 (88.9) 4 (80.0)
MS, Metabolic Syndrome.
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of diabetes was > 20 years, it was not different in men
or women when compared to subjects without MS.
Nephropathy was more prevalent in women with MS
and whose duration of diabetes was < 10 years and 11-
20 years but the prevalence was not different when the
duration of diabetes was > 20 years.
To evaluate the relation between the presence of dia-
betic microvascular complications and individual MS
components, we performed a multiple logistic regression
analysis by adjusting variables such as age, gender,
smoking and alcohol (Table 7). The results showed that
the independent risk factors for retinopathy were glyco-
sylated hemoglobin - OR 1.16 (95% CI 1.07-1.26)
and duration of diabetes - OR 1.13 (95% CI 1.09-1.16).
For nephropathy, the risk factors were glycosylated
hemoglobin - OR 1.24 (95% CI 1.15-1.34), duration of
diabetes - OR 1.04 (95% CI 1.01-1.07) and hypertension
- OR 1.80 (95% CI 1.20-2.70). For neuropathy, the inde-
pendent risk factors came out to be reduced serum
HDL cholesterol - OR 1.03 (95% CI 1.01-1.05) and
increased waist circumference - OR 1.02 (1.00-1.04).
Discussion
The present study reports an alarmingly high prevalence
of MS, using IDF criteria, in subjects with type 2
diabetes mellitus in a population-based study. One of
the IDF criteria for MS, the increased fasting plasma
glucose ≥ 100 mg/dl or pre-existing diabetes, was pre-
sent in all of the participants of the study; therefore, the
“metabolic syndrome” in this study is not exactly the
same as MS in general sense. In our cohort, almost
every three out of four subjects with type 2 diabetes had
MS. A similar high prevalence was reported by Surana
et al [25] in urban Indian population with type 2 dia-
betes (77.2%) and by Foucan et al [26] in Indian immi-
grants in the USA with diabetes (77%). This prevalence
of MS in the South Indian population with diabetes is
more than two-fold higher than the reported prevalence
in the general urban Indian population [27]. Using a
similar definition as ours (IDF), Terauchi et al [13] and
Bonadonna et al [11] reported the prevalence of MS to
be 58.5% and 77.6% respectively, which was comparable
to that observed in our study.
The present study has observed gender-wise differ-
ences with respect to prevalence of MS and its influence
on microangiopathies. The MS, in the defined popula-
tion of type II diabetes mellitus, was more prevalent in
women than men (Table 1); there was a positive correla-
tion between the number of components of MS and all
types of microangiopathies (Table 5) in women. Like
our study, Ghani et al [28] and Bonadonna et al [11]
Table 7 Multiple logistic model for risk factors for microangiopathies
Overall Men Women
Independent variables OR (95% CI) p OR (95% CI) * p OR (95% CI)
† p
Retinopathy
Glycosylated Hemoglobin 1.16 (1.07-1.26) < 0.0001 1.14 (1.02-1.28) 0.020 1.19 (1.07-1.34) 0.002
Duration of Diabetes 1.13 (1.09-1.16) < 0.0001 1.13 (1.08-1.17) < 0.0001 1.13 (1.08-1.18) < 0.0001
Hypertension 1.18 (0.80-1.77) 0.392 1.09 (0.65-1.82) 0.746 1.41 (0.74-2.69) 0.297
Elevated serum Triglyceride 1.01 (0.99-1.00) 0.560 1.00 (0.99-1.00) 0.256 1.00 (0.99-1.00) 0.857
Reduced serum HDL-Cholesterol 1.01 (0.99-1.03) 0.254 1.03 (1.00-1.06) 0.038 0.99 (0.97-1.02) 0.618
Increased Waist circumference 0.98 (0.96-1.01) 0.188 0.96 (0.93-0.99) 0.037 1.01 (0.98-1.04) 0.663
Nephropathy
Glycosylated Hemoglobin 1.24 (1.15-1.34) < 0.0001 1.19 (1.07-1.34) 0.002 1.27 (1.15-1.39) < 0.0001
Duration of Diabetes 1.04 (1.01-1.07) 0.008 1.04 (1.00-1.08) 0.052 1.04 (0.99-1.08) 0.076
Hypertension 1.80 (1.20-2.70) 0.004 1.50 (0.86-2.63) 0.155 2.17 (1.19-3.93) 0.011
Elevated serum Triglyceride 1.00 (0.99-1.00) 0.976 0.99 (0.99-1.00) 0.661 1.00 (0.99-1.00) 0.473
Reduced serum HDL-Cholesterol 0.99 (0.98-1.02) 0.857 1.01 (0.98-1.04) 0.612 0.99 (0.97-1.01) 0.450
Increased Waist circumference 1.02 (1.00-1.04) 0.055 1.03 (0.99-1.07) 0.064 1.01 (0.99-1.04) 0.289
Neuropathy
Glycosylated Hemoglobin 1.05 (0.97-1.14) 0.192 1.08 (0.96-1.21) 0.198 1.03 (0.92-1.15) 0.596
Duration of Diabetes 1.02 (0.99-1.05) 0.181 1.01 (0.97-1.05) 0.653 1.03 (0.98-1.07) 0.215
Hypertension 1.19 (0.80-1.76) 0.384 0.87 (0.51-1.48) 0.607 1.83 (0.98-3.44) 0.059
Elevated serum Triglyceride 1.00 (0.99-1.00) 0.381 1.00 (0.99-1.00) 0.313 1.00 (0.99-1.00) 0.496
Reduced serum HDL-Cholesterol 1.03 (1.01-1.05) 0.001 1.06 (1.03-1.09) < 0.0001 1.00 (0.98-1.03) 0.806
Increased Waist circumference 1.02 (1.00-1.04) 0.043 1.01 (0.97-1.04) 0.640 1.03 (1.00-1.06) 0.027
* All factors adjusted with age, gender, glycosylated hemoglobin, hemoglobin, socioeconomic status, smoking status and alcohol status.
† All factors adjusted with age, glycosylated hemoglobin, hemoglobin, socioeconomic status, smoking status and alcohol status.
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however Shimajiri et al [4] reported a higher prevalence
in men. Among the Indian diabetic population, a higher
prevalence of MS in women was reported by Surana
et al [ 2 5 ] .T h e yp r o p o s e dt h ec a u s et ob eah i g h e rp r e -
valence of low HDL and central obesity in women,
which could partially be attributed to the lower cut-off
for waist circumference and higher cut-off for HDL in
w o m e na sc o m p a r e dt om e n .I no u rs t u d y ,w ea l s o
noted a higher BMI and lower HDL cholesterol in
women as compared to men. But the waist circumfer-
ence was lower in women despite the lower cut-off,
which suggests that there are other factors which
increase the prevalence of MS in women. Bonadonna
et al [11] also commented in their study that this trend
could be both due to a true biological phenomenon or a
suboptimal choice of gender-specific diagnostic thresh-
olds. Because of these gender-wise differences, female
gender should become a focus of high risk target-
screening, and attempts should be made to normalize
each component of MS so as to minimize the risk of
microangiopathies.
Shimajiri et al [4] reported that the prevalence of MS
decreases along with an increase in the duration of dia-
betes. They suggested the possible reason to be a
decreased BMI as a result of medical intervention in the
lifestyle of long term diabetic patients. In our study, we
noted this trend only in men. We feel that the better
accessibility to medical care and more health awareness
among men in our country can be a factor responsible
for this. Whether there are other biological or hormonal
factors playing a role is not known. We also observed
different trends in obesity indices in men and women in
the same study cohort, which is possibly related to post-
menopausal hormonal changes in women [29]. This
might also explain the gender differences in the current
study.
Similar to our finding, Ghani et al [28] also found an
association of MS with less duration of diabetes. The
occurrence of microangiopathies in diabetes mellitus is
influenced by several of the components of the MS; this
implies a possible relationship between microangiopa-
thies and MS. The association of MS with microvascular
complications of type 2 diabetes i.e. diabetic retinopathy,
nephropathy and neuropathy has been studied in many
reports [4,9,11,28], They found the increased prevalence
of all three complications in patients with diabetes using
different definitions of MS. Kawasaki et al [12] used the
IDF criteria and reported that the associations between
MS and retinal microvascular signs appeared mainly dri-
ven by the associations with larger waist circumference.
Isomaa et al [5] reported that MS was strongly asso-
ciated with microalbuminuria but had little effect on the
development of retinopathy and neuropathy. However, a
study in Japanese patients, on the other hand, did not
show any statistically significant association of MS with
the prevalence of microvascular complications in type 2
diabetes mellitus [13]. They attributed it to possible eth-
nicity related differences because in Asian population,
MS has also been reported to be non predictive of cor-
onary artery disease in contrast to the results in Cauca-
sian population. In our study, we found a similar lack of
association between MS and the increased prevalence of
microvascular disease.
Some previous studies have reported an increase in
the prevalence of microangiopathies when patients were
grouped according to the number of MS components
[9,28,30]. In men, we found that there was no trend of
increase in diabetic microvascular complications with an
increase in the MS features. However, in women, there
was a statistically significant increase in the prevalence
of diabetic microangiopathies with an increase in the
MS components.
On evaluating the influence of the duration of diabetes
on the prevalence of microangiopathies in patients with
MS, we found that there was a significant association
between MS and the prevalence of microangiopathies in
subjects with type 2 diabetes mellitus in the early course
of the disease which disappeared with the increasing
duration of diabetes in both men and women. This sug-
gests that MS might have a more significant influence
on increasing the prevalence of microvascular disease in
recent diabetics, but gradually with increasing duration
of diabetes, this influence decreases. One possible expla-
nation for this could be better metabolic control in dia-
betic patients due to increasing awareness with longer
duration of diabetes. We did find this trend in the pre-
sent study; subjects with longer duration of diabetes
(> 20 years) had better metabolic control (FBS< 110 mg
%) than those with shorter duration of diabetes (0-10
and 11-20 years). The FBS < 110 mg% was noted in
61.8%, 73.7% and 79.2% of subjects with duration of dia-
betes mellitus being 0-10 years, 11-20 years and > 20
years, respectively (p = 0.005).
We found the risk factors for retinopathy to be glyco-
sylated hemoglobin and duration of diabetes, for
nephropathy to be glycosylated hemoglobin, duration of
diabetes, hypertension, increased body mass index and
increased waist circumference and for neuropathy to be
reduced serum HDL cholesterol on multivariate analysis.
Different associations have also been reported in pre-
vious studies [5,12,13]. We also found an association of
waist circumference with nephropathy as was reported
by Hanai et al [30].
Conclusions
The strength of current study is that it was a population
based study that used standardized methods for
Raman et al. Diabetology & Metabolic Syndrome 2010, 2:67
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mellitus. However, the causalr e l a t i o n s h i pc o u l dn o tb e
assessed because of the cross sectional nature of study.
T h ep r e v a l e n c ea n dr i s kf a c t o r so fm i c r o a n g i o p a t h i e s
among subjects with MS may also be influenced by pre-
sence of diabetes mellitus.
This study reports the prevalence and risk factors for
MS in subjects with type 2 diabetes. The gender differ-
ences in the prevalence and the risk factors for MS in
the population with diabetes need further confirmation
in a larger prospective study.
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